The Company believes tecarfarin is the solution for this unmet need.
At the recent
In the report, study author Geert-Jan Geersing, MD, PhD, of the
Cadrenal is developing tecarfarin, a novel Vitamin K Antagonist, targeted for indications where existing VKAs fail to achieve sufficiently stable anticoagulation and DOACs (Eliquis-class drugs) are not widely prescribed.
'The findings of the FRAIL-AF study highlight the benefits of VKAs compared to DOACs in an additional unique patient population,' commented
Currently, tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with ESKD and AFib, providing for 7-year marketing exclusivity.
Based on management's market analysis studies and expected adoption rates, these three rare medical conditions present a U.S. market opportunity in excess of
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions. Tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with ESKD and AFib. Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin) used in the prevention of thrombosis. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease.
Safe Harbor Statement
Any statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include statements regarding tecarfarin being the solution for an improved Vitamin K Antagonist, tecarfarin providing improved outcomes for patients with certain rare medical conditions and End-Stage Kidney Disease with Atrial Fibrillation; Left Ventricular Assist Devices and Antiphospholipid Syndrome presenting a U.S. market opportunity in excess of
The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to be an improved Vitamin K Antagonist, the ability to advance tecarfarin within patients with rare medical conditions, the ability to penetrate the U.S. market for patients with End-Stage Kidney Disease with Atrial Fibrillation; Left Ventricular Assist Devices and Antiphospholipid Syndrome and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended
Contact:
Tel: 858-337-0766
Email: press@cadrenal.com
(C) 2023 Electronic News Publishing, source